Table 1.

The characteristics of included trials.

Author	Year	NCT Number	RCT name	Clinical Trial Phase	Intervention	Total (n)	Median Age(range)	Male n(%)	ECOGPS=0 n(%)	MPs Median, months (95% CI)	mOS Median, months (95% CI)	Follow-up (month) Median, months (range or IQR)	Level of evidence according to the GRADE system	Level of evidence according to the Oxford System
Fradet et al. (11)	2019	NCT02256436	KEYNOTE-045	III	Pembrolizumab	270	67 (29–88)	200 (74)	119 (44)	2.1 (2.0–2.2)	10.1 (8.0–12.3)	27.7 (median)	Grade 1	1b
Powles et al. (28)	2018	NCT02302807	IMvigor211	III	Atezolizumab	467	67 (43–88)	81 (70)	61 (53)	NA	8.6 (7.8–9.6)	17·3 (range, 0–24·5)	Grade 1	1b
Ohyama et al. (29)	2019	NCT 02387996	CheckMate 275	II	Nivolumab	270	66 (38–90)	211 (78)	145 (54)	1.9 (1.9–2.3)	8.6 (6.1–11.3)	33.7 (minimum)	Grade 2	2b
Rosenberg et al. (30)	2016	NCT02108652	IMvigor210 (Cohort 2)	II	Atezolizumab	310	66 (32–91)	241 (78)	117 (38)	2.7 (2.1–3.9)	7.9 (6.6–9.3)	11.7 (IQR, 11·4–12·2)	Grade 2	2b
Sharma et al. (31)	2016	NCT01928394	CheckMate 032	I/II	Nivolumab	78	66 (31–85)	54 (69)	42 (54)	NA	9.7 (7.3–16.2)	15.2 (IQR, 12·9–16·8)	Grade 2	2b
Powles et al. (32)	2017	NCT01693562	Study 1108	I/II	Durvalumab	191	67 (34–88)	136 (71)	64 (34)	1.5 (1.4–1.9)	18.2 (8.1-NE)	5.8 (range, 0.4–25.9)	Grade 2	2b
Plimack et al. (33)	2017	NCT01848834	KEYNOTE-012	Ib	Pembrolizumab	33	70 (44–85)	23 (70)	9 (27)	2 (2–4)	13 (5–20)	13 (IQR, 5–23)	Grade 2	2b
Apolo et al. (34)	2017	NCT01772004	JAVELIN Solid (dose-expansion cohort)	Ib	Avelumab	44	68 (63–73)	30 (68)	19 (43)	2.9 (1.5–4.4)	13.7 (8.5-NE)	16.5 (IQR, 15.8–16.7)	Grade 2	2b

IQR, interquartile range; HR, hazard ratio; NA, not available, ICI, immune checkpoint inhibitor; Ctl, control.